Log in to save to my catalogue

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8655576

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

Multiple myeloma (MM) remains incurable despite the number of novel therapies that have become available in recent years. Occasionally, a patient with MM will develop an amyloid light-chain (AL) amyloidosis with organ dysfunction. Chimeric antigen receptor T-cell (CART) therapy has become a promising approach in treating hematological malignancies....

Alternative Titles

Full title

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8655576

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8655576

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2021-003783

How to access this item